Emcure Pharmaceuticals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Emcure Pharmaceuticals Ltd reported a 4.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 22.7%.
• Its expenses for the quarter were up by 2.2% QoQ and 20.9% YoY.
• The net profit increased 20.0% QoQ and increased 36.2% YoY.
• The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 15.5 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its broad range of generic and branded pharmaceutical products. The company operates across various therapeutic areas, offering solutions in cardio-metabolic, pain management, oncology, and more. As a key participant in the pharmaceutical sector, Emcure has been involved in the development and manufacturing of a wide array of medicines that cater to both domestic and international markets. While the company has made significant strides over the years, specific recent developments or strategic initiatives are not detailed in the provided data.

Revenue

In Q1FY27, Emcure Pharmaceuticals Ltd reported a total income of ₹2582.52 crores, marking a 4.4% increase from the ₹2473.70 crores recorded in Q4FY26. When compared to Q1FY26, which saw a total income of ₹2104.23 crores, there is a notable year-over-year growth of 22.7%. This upward trajectory in revenue reflects an ongoing expansion in the company's operations or market presence during the period under review. The increase in total income underscores the company's ability to enhance its revenue streams over both the quarterly and yearly periods.

Profitability

For the quarter ending Q1FY27, Emcure Pharmaceuticals Ltd achieved a profit before tax of ₹393.53 crores, which reflects a 15.3% increase from ₹341.18 crores in the previous quarter, Q4FY26. On a year-over-year basis, this represents a substantial increase of 35.3% from ₹290.76 crores in Q1FY26. The profit after tax for the same quarter stood at ₹292.49 crores, a 20.0% rise from the previous quarter's ₹243.73 crores and a 36.2% increase from ₹214.79 crores in the corresponding quarter of the previous year. These figures indicate strong profitability growth within the company over the observed periods. The tax expenses for the quarter were ₹101.03 crores, showing moderate growth both quarter-over-quarter and year-over-year.

Operating Metrics

Emcure Pharmaceuticals Ltd's earnings per share (EPS) for Q1FY27 was ₹15.50, up 20.7% from ₹12.84 in Q4FY26, and a 41.9% increase from ₹10.92 in Q1FY26. This growth in EPS suggests enhanced shareholder value and profitability per share over the periods analyzed. Total expenses for Q1FY27 were ₹2188.99 crores, representing a 2.2% increase from the previous quarter and a 20.9% rise from the same quarter in the previous year. The controlled increase in expenses relative to income growth may reflect effective cost management strategies during the period. These metrics provide insight into the company's operational efficiency and financial health over the specified timeframes.